1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Nonalcoholic Steatohepatitis (NASH) Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Obeticholic acid?OCA?
1.2.3 Selonsertib
1.3 Market by Application
1.3.1 Global Nonalcoholic Steatohepatitis (NASH) Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 Hospital Pharmacy
1.3.3 Online Provider
1.3.4 Retail Pharmacy
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Nonalcoholic Steatohepatitis (NASH) Market Perspective (2017-2028)
2.2 Nonalcoholic Steatohepatitis (NASH) Growth Trends by Region
2.2.1 Nonalcoholic Steatohepatitis (NASH) Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Nonalcoholic Steatohepatitis (NASH) Historic Market Size by Region (2017-2022)
2.2.3 Nonalcoholic Steatohepatitis (NASH) Forecasted Market Size by Region (2023-2028)
2.3 Nonalcoholic Steatohepatitis (NASH) Market Dynamics
2.3.1 Nonalcoholic Steatohepatitis (NASH) Industry Trends
2.3.2 Nonalcoholic Steatohepatitis (NASH) Market Drivers
2.3.3 Nonalcoholic Steatohepatitis (NASH) Market Challenges
2.3.4 Nonalcoholic Steatohepatitis (NASH) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Nonalcoholic Steatohepatitis (NASH) Players by Revenue
3.1.1 Global Top Nonalcoholic Steatohepatitis (NASH) Players by Revenue (2017-2022)
3.1.2 Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share by Players (2017-2022)
3.2 Global Nonalcoholic Steatohepatitis (NASH) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Nonalcoholic Steatohepatitis (NASH) Revenue
3.4 Global Nonalcoholic Steatohepatitis (NASH) Market Concentration Ratio
3.4.1 Global Nonalcoholic Steatohepatitis (NASH) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Nonalcoholic Steatohepatitis (NASH) Revenue in 2021
3.5 Nonalcoholic Steatohepatitis (NASH) Key Players Head office and Area Served
3.6 Key Players Nonalcoholic Steatohepatitis (NASH) Product Solution and Service
3.7 Date of Enter into Nonalcoholic Steatohepatitis (NASH) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Nonalcoholic Steatohepatitis (NASH) Breakdown Data by Type
4.1 Global Nonalcoholic Steatohepatitis (NASH) Historic Market Size by Type (2017-2022)
4.2 Global Nonalcoholic Steatohepatitis (NASH) Forecasted Market Size by Type (2023-2028)
5 Nonalcoholic Steatohepatitis (NASH) Breakdown Data by Application
5.1 Global Nonalcoholic Steatohepatitis (NASH) Historic Market Size by Application (2017-2022)
5.2 Global Nonalcoholic Steatohepatitis (NASH) Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Nonalcoholic Steatohepatitis (NASH) Market Size (2017-2028)
6.2 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2017-2022)
6.3 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Nonalcoholic Steatohepatitis (NASH) Market Size (2017-2028)
7.2 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2017-2022)
7.3 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size (2017-2028)
8.2 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2017-2022)
8.3 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Nonalcoholic Steatohepatitis (NASH) Market Size (2017-2028)
9.2 Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2017-2022)
9.3 Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size (2017-2028)
10.2 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2017-2022)
10.3 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Company Detail
11.1.2 AstraZeneca Business Overview
11.1.3 AstraZeneca Nonalcoholic Steatohepatitis (NASH) Introduction
11.1.4 AstraZeneca Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
11.1.5 AstraZeneca Recent Development
11.2 Arena Pharmaceuticals
11.2.1 Arena Pharmaceuticals Company Detail
11.2.2 Arena Pharmaceuticals Business Overview
11.2.3 Arena Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Introduction
11.2.4 Arena Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
11.2.5 Arena Pharmaceuticals Recent Development
11.3 GSK
11.3.1 GSK Company Detail
11.3.2 GSK Business Overview
11.3.3 GSK Nonalcoholic Steatohepatitis (NASH) Introduction
11.3.4 GSK Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
11.3.5 GSK Recent Development
11.4 Novo Nordisk
11.4.1 Novo Nordisk Company Detail
11.4.2 Novo Nordisk Business Overview
11.4.3 Novo Nordisk Nonalcoholic Steatohepatitis (NASH) Introduction
11.4.4 Novo Nordisk Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
11.4.5 Novo Nordisk Recent Development
11.5 Roche
11.5.1 Roche Company Detail
11.5.2 Roche Business Overview
11.5.3 Roche Nonalcoholic Steatohepatitis (NASH) Introduction
11.5.4 Roche Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
11.5.5 Roche Recent Development
11.6 Vivus
11.6.1 Vivus Company Detail
11.6.2 Vivus Business Overview
11.6.3 Vivus Nonalcoholic Steatohepatitis (NASH) Introduction
11.6.4 Vivus Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
11.6.5 Vivus Recent Development
11.7 Arisaph Pharmaceuticals
11.7.1 Arisaph Pharmaceuticals Company Detail
11.7.2 Arisaph Pharmaceuticals Business Overview
11.7.3 Arisaph Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Introduction
11.7.4 Arisaph Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
11.7.5 Arisaph Pharmaceuticals Recent Development
11.8 Cempra Pharmaceuticals
11.8.1 Cempra Pharmaceuticals Company Detail
11.8.2 Cempra Pharmaceuticals Business Overview
11.8.3 Cempra Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Introduction
11.8.4 Cempra Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
11.8.5 Cempra Pharmaceuticals Recent Development
11.9 Galectin Therapeutics
11.9.1 Galectin Therapeutics Company Detail
11.9.2 Galectin Therapeutics Business Overview
11.9.3 Galectin Therapeutics Nonalcoholic Steatohepatitis (NASH) Introduction
11.9.4 Galectin Therapeutics Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
11.9.5 Galectin Therapeutics Recent Development
11.10 Galmed Pharmaceuticals
11.10.1 Galmed Pharmaceuticals Company Detail
11.10.2 Galmed Pharmaceuticals Business Overview
11.10.3 Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Introduction
11.10.4 Galmed Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
11.10.5 Galmed Pharmaceuticals Recent Development
11.11 Genfit
11.11.1 Genfit Company Detail
11.11.2 Genfit Business Overview
11.11.3 Genfit Nonalcoholic Steatohepatitis (NASH) Introduction
11.11.4 Genfit Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
11.11.5 Genfit Recent Development
11.12 Gilead
11.12.1 Gilead Company Detail
11.12.2 Gilead Business Overview
11.12.3 Gilead Nonalcoholic Steatohepatitis (NASH) Introduction
11.12.4 Gilead Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
11.12.5 Gilead Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
